Neuro-ophthalmology

World's Most Influential People in Ophthalmology

Retrieved on: 
Giovedì, Maggio 9, 2024
Education, FDA, Bascom Palmer Eye Institute, Genetics, Teaching, Surgeon, Paratriathlon, Neuro-ophthalmology, Leach, Strabismus, Cataract, Knowledge, Bascom H. Palmer, Gedde, Eye, DRS, Retina, Vision science, Quality of life, Publication, Research, Bevacizumab, Artificial intelligence, Suture, Health, M.A, Choroideremia, Medeiros, Vance DeGeneres, University, Retinitis pigmentosa, Epidemiology, American Journal, Power, Patient, Physician, Uveitis, Glaucoma, Nursing

MIAMI, May 9, 2024 /PRNewswire/ -- Fifteen Bascom Palmer Eye Institute physicians were selected for the 2024 Power List, a prestigious selection of the world's 100 most influential people shaping the future of eye care, as published by The Ophthalmologist magazine. Drs. Eduardo C. Alfonso, Kendall Donaldson, Hilda Capó, Janet Davis, Harry Flynn, Anat Galor, Steven Gedde, Ranya Habash, Carol Karp, Jaclyn Kovach, Byron Lam, Felipe Medeiros, Richard Parrish, Philip Rosenfeld, and Sonia Yoo were named to the 2024 Power List. Bascom Palmer Eye Institute is the Department of Ophthalmology for the University of Miami Miller School of Medicine and UHealth – University of Miami Health System.

Key Points: 
  • Bascom Palmer Eye Institute is the Department of Ophthalmology for the University of Miami Miller School of Medicine and UHealth – University of Miami Health System.
  • From cutting-edge treatments to groundbreaking research, these doctors are pushing boundaries and setting new standards in ophthalmology."
  • Alfonso, the holder of the Kathleen and Stanley J. Glaser Chair in Ophthalmology, was also named to the Ophthalmologist Power Lists 2014, 2016, 2018, 2022, and 2023.
  • Holder of the John T. Flynn Chair in Ophthalmology, Hilda Capó, M.D., specializes in pediatric ophthalmology and adult strabismus.

Doheny Eye Institute Announces Upcoming Presentations at ARVO 2024 Annual Meeting

Retrieved on: 
Mercoledì, Aprile 24, 2024
Grand Hyatt Seattle, Srinivas, Research, Diabetic retinopathy, PDT, MD, Doctor of Philosophy, Artificial intelligence, Booth, Neuro-ophthalmology, Eye, Breakfast, RSVP, Seattle Convention Center, Annual general meeting, Doheny Eye Institute, Pine Street, Imaging, ARVO, Knowledge

PASADENA, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Doheny Eye Institute , one of the nation’s leading vision research institutions, announced that more than 25 of its scientists and clinician-scientists will present their latest research during the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, the premiere gathering for eye and vision scientists from across the globe.

Key Points: 
  • PASADENA, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Doheny Eye Institute , one of the nation’s leading vision research institutions, announced that more than 25 of its scientists and clinician-scientists will present their latest research during the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, the premiere gathering for eye and vision scientists from across the globe.
  • Doheny Eye Institute and UCLA Stein Eye Institute will also be exhibiting together onsite at Booth #4515.
  • “Doheny Eye Institute is eager to share our latest findings and exchange insights with other leaders in vision research during the ARVO Annual Meeting,” said Deborah A. Ferrington, PhD, Chief Scientific Officer at Doheny Eye Institute.
  • At the conclusion of ARVO 2024, SriniVas R. Sadda, MD, the Director of Artificial Intelligence & Imaging Research at Doheny, will officially step into his role as President of ARVO.

GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024

Retrieved on: 
Martedì, Marzo 12, 2024
Research, Neurology, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Mutation, Disease, Nadir, Patient, CRR, Eye, Idebenone, Natural history, Phase, Multimedia, Neuro-ophthalmology, ND4, Interval (mathematics), AAC, Medical imaging

The meta-analyses are the first to focus solely on patients with the m.11778G>A ND4 mutation, which is the most common mutation and one with a poor visual prognosis1.

Key Points: 
  • The meta-analyses are the first to focus solely on patients with the m.11778G>A ND4 mutation, which is the most common mutation and one with a poor visual prognosis1.
  • This gradient of recovery, based on the CRR measure of visual improvement, is observed at both eye level and patient level (response in one or both eyes).
  • There is no overlap in confidence intervals when LUMEVOQ® is compared to idebenone and to natural history, indicating a positive difference in visual outcomes.
  • Follow-up of patients in the Phase III REFLECT study of LUMEVOQ® is ongoing, with topline results at Year 4 of follow-up expected this month.

SightMD Celebrates 22 Physicians Named Castle Connolly's 2024 Top Doctors

Retrieved on: 
Venerdì, Febbraio 9, 2024
Health, Castle Connolly Medical, Ophthalmology, Medicine, Physician, Neuro-ophthalmology, Patient, Research, Nursing

HAUPPAUGE, N.Y., Feb. 9, 2024 /PRNewswire-PRWeb/ -- SightMD, a premier provider of comprehensive eye care services, proudly announces that an impressive roster of 22 of its esteemed physicians have been recognized as Castle Connolly's Top Doctors for 2024. This esteemed recognition reaffirms SightMD's commitment to providing exceptional eye care through a team of highly skilled and dedicated professionals.

Key Points: 
  • SightMD, a premier provider of comprehensive eye care services, proudly announces that an impressive roster of 22 of its esteemed physicians have been recognized as Castle Connolly's Top Doctors for 2024.
  • HAUPPAUGE, N.Y., Feb. 9, 2024 /PRNewswire-PRWeb/ -- SightMD, a premier provider of comprehensive eye care services, proudly announces that an impressive roster of 22 of its esteemed physicians have been recognized as Castle Connolly's Top Doctors for 2024.
  • "We are immensely proud to have 22 of our physicians named as Castle Connolly's Top Doctors for 2024.
  • SightMD congratulates all the physicians honored as Castle Connolly's 2024 Top Doctors and expresses gratitude for their unwavering commitment to excellence in patient care.

Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage

Retrieved on: 
Giovedì, Dicembre 7, 2023
Neuro-ophthalmology, European Commission, Cardiology, Rheumatology, Executive Committee, Medical director, CMC, CCO, CDMO, CGMP, Doctor of Philosophy, Actelion, Civil service commission, Vamorolone, Endocrinology, DSM-IV codes, Erasmus University Rotterdam, Patient, Head, Organization, Neurology, Technical

Both will join the six-member Executive Committee effective January 1, 2024.

Key Points: 
  • Both will join the six-member Executive Committee effective January 1, 2024.
  • “Santhera is transitioning to the commercial phase and will make AGAMREE® (vamorolone) available to patients in Europe starting in Germany in early 2024, subject to approval by the European Commission.
  • Notably, he was instrumental in establishing Santhera’s European commercial operations and successfully launching the rare disease product RAXONE® in Europe which was later divested to Chiesi Group.
  • Before joining Santhera, Geert Jan held positions as Medical Director, Business Unit Director and General Manager in start-up teams in Serono, Actelion and InterMune.

SightMD Welcomes Robert Spector, MD to its expert team in New York

Retrieved on: 
Lunedì, Agosto 14, 2023
Learning, Music, University, American Board of Ophthalmology, Teaching, American Academy, University of Iowa, American Academy of Ophthalmology, Golf, American Academy of Pediatrics, Bascom Palmer Eye Institute, Public key certificate, American Board of Commissioners for Foreign Missions, MD, Patient, Case Western Reserve University School of Medicine, Cataract, Neuro-ophthalmology, Family, Society, Nursing, Pediatric ophthalmology, Ophthalmology, Growth, Medicine

HAUPPAUGE, N.Y., Aug. 14, 2023 /PRNewswire-PRWeb/ -- SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes Robert Spector, MD to its expert team.

Key Points: 
  • SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes Robert Spector, MD to its expert team.
  • HAUPPAUGE, N.Y., Aug. 14, 2023 /PRNewswire-PRWeb/ -- SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes Robert Spector, MD to its expert team.
  • Dr. Robert T. Spector, M.D., F.A.C.S.
  • SightMD is actively seeking ophthalmology professionals who are interested in joining our outstanding team.

EyeCare Partners Introduces Advanced Comprehensive Ophthalmology Fellowship (ACOF) as Pathway to Accelerate Skill Development and Address the Need for More Trained Ophthalmologists

Retrieved on: 
Martedì, Giugno 27, 2023
Education, Training, Optical, Health, Retina, Glaucoma, Cornea, Learning, Low-residency program, Microbiology, Eastern Virginia Medical School, ECP, Partner, EVMS, Research, Private practice, Molecular biology, Telecanthus, Neuro-ophthalmology, Patient, Physician, Nursing, Thomas, Fellows, Pharmacology, Hospital, Veterinary medicine, Ophthalmology

ACOF is a one-year program that will provide comprehensive training to residency graduates in the latest advancements in ophthalmology, including diagnostic and therapeutic techniques, surgical procedures and clinical research.

Key Points: 
  • ACOF is a one-year program that will provide comprehensive training to residency graduates in the latest advancements in ophthalmology, including diagnostic and therapeutic techniques, surgical procedures and clinical research.
  • ACOF was developed by the EyeCare Partners Innovation Center, which was launched last fall to advance eye care quality, research and education.
  • “Traditional fellowships focus on subspecialities like glaucoma, cornea, anterior segment, retina, neuro-ophthalmology and oculoplastics.
  • Applications for ACOF are now open, and interested and qualified candidates are encouraged to apply at https://www.eyecare-partners.com/acof/ .

Oculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023

Retrieved on: 
Lunedì, Giugno 26, 2023
University of Southern California, DME, Stanford University, Partner (business rank), Teaching hospital, Alcon, Lotte New York Palace Hotel, SAB, University, Neuroscience, OCS, Genentech, Stanford University School of Medicine, Retina, POC, Keck School of Medicine of USC, Neuro-ophthalmology, Master of Science, Clinical research, Webcast, CME, Drug development, University of Paris, Q&A, AON, University of Nevada, Reno School of Medicine, Diabetic retinopathy, Reno 1868 FC, Neuro, Medical director, Novartis, Fellow, USC Eye Institute, Tourism, Pharmaceutical industry, Management, Development, Ophthalmology, MD, Pecten oculi, Medicine

ZUG, Switzerland and BOSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that it will host its first R&D Day featuring multiple experts to showcase its clinical programs targeting retina diseases on Tuesday, July 11, 2023, from 10:00 AM – 12:00 PM EDT.

Key Points: 
  • ZUG, Switzerland and BOSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that it will host its first R&D Day featuring multiple experts to showcase its clinical programs targeting retina diseases on Tuesday, July 11, 2023, from 10:00 AM – 12:00 PM EDT.
  • Those interested can participate in the event either in-person at the Lotte New York Palace Hotel, or virtually via webcast.
  • To register for the event, please click here .
  • The additional expert panelists participating in the Q&A session include:
    Pravin Dugel, MD: Oculis Board of Directors member, retina specialist, and President of Iveric Bio.

ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights

Retrieved on: 
Giovedì, Giugno 15, 2023
Acceleration, Exercise, TED, SLRN, IPO, POC, IPR, D, Abscess, Enthesitis, Public, Quality of life, American Academy, Research, Doctor of Philosophy, Connective tissue, Graves' ophthalmopathy, Hidradenitis suppurativa, Psoriatic arthritis, Acquisition, MD, AAD, Patient, American Academy of Dermatology, LOS, Data monitoring committee, Hives, Neuro-ophthalmology, III, DMC, Disease, Autoimmunity, Inflammation, Life insurance, Pharmaceutical industry, HS

With the proceeds of our recent initial public offering, we will continue to drive towards key value-driving milestones to deliver efficiently on our development plans.

Key Points: 
  • With the proceeds of our recent initial public offering, we will continue to drive towards key value-driving milestones to deliver efficiently on our development plans.
  • Part B of the Phase 2b/3 trial completed enrollment early and top-line results are now anticipated in Q3 2023.
  • Net Loss: Net loss totaled $176.5 million for the first quarter of 2023, compared to $16.1 million for the first quarter of 2022.
  • This includes the one-time $123.1 million IPR&D charge and $10.0 million license payment, both related to the acquisition of ValenzaBio.

Oculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association of Business and Economics

Retrieved on: 
Lunedì, Giugno 12, 2023
Knowledge, Retina, Mohammed bin Rashid Al Maktoum, Education, DME, Icelandic Association for Search and Rescue, Diabetic retinopathy, Eye, Clinical trial, Business, BBVA Foundation Frontiers of Knowledge Award, Quality of life, Þorsteinn, OCS, Research, Inflammation, Solubility, Dexamethasone, Economics, Pain, Neuro-ophthalmology, Patient, Ophthalmology, Professor, Icelandic, Pharmaceutical industry, Orbicularis oculi muscle

ZUG, Switzerland and BOSTON, June 12, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced it has won the 2023 Knowledge Award from the Icelandic Association of Business and Economics.

Key Points: 
  • ZUG, Switzerland and BOSTON, June 12, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced it has won the 2023 Knowledge Award from the Icelandic Association of Business and Economics.
  • Oculis has received the Knowledge Award this year for its research developing Oculis’ OPTIREACH solubilizing formulation technology, by Professors Stefánsson and Loftsson, Oculis’ co-founded, which took place in Oculis’ laboratory in Iceland.
  • Riad Sherif, M.D., CEO of Oculis, said: “I’m delighted that Oculis has been recognized with the Icelandic Knowledge Award this year.
  • During the event, companies that have demonstrated excellence in relation to the chosen subject are awarded for their success which includes the prestigious Knowledge Award.